naulicreative / Shutterstock.com
The consequences of the Brexit vote for the life sciences sector will depend on the UK’s relationship with the EU once the negotiations are concluded, as Christina Guazzi and Nina Schäffner of Freshfields Bruckhaus Deringer explain.
One potential outcome of the British vote to leave the EU is the divergence of regulatory frameworks for bringing pharmaceutical products to market in the UK and the EU—UK IP rights may split from harmonised EU systems of protection.
UK life sciences companies will be hit hardest by these changes but they are also set to affect all major EU and international players with activities across the UK and the EU.
Of course, much will depend on the UK’s relationship with the EU once Brexit negotiations are concluded. If the UK remains in the European Economic Area (EEA), then the adjustments for the pharmaceutical industry are likely to be less significant.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Christina Guazzi, Nina Schäffner, Freshfields Bruckhaus Deringer, S[Cs, EEA, Brexit, life sciences, UPC, market exclusivity, EMA, MHRA, patent,
